

We show that breast cancer genomes are rich in predictive and prognostic value. We propose a two-step model for effective clinical application. First, the identification of candidates for targeted therapies or clinical trials using highly individualised genomic markers. Second, for patients without such features, the implementation of enhanced prognostication using genomic features alongside existing clinical decision-making factors.
Oncology
|31st Dec, 2025
|Journal of the American Medical Association
Oncology
|15th Jan, 2026
|The Lancet
Oncology
|15th Jan, 2026
|The Lancet
Oncology
|15th Jan, 2026
|The Lancet
Oncology
|15th Jan, 2026
|The Lancet
Oncology
|15th Jan, 2026
|The Lancet
Oncology
|15th Jan, 2026
|The Lancet